The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

We obviously, rolled out Zepbound and this is -- we're just now ... that are now going from just weight loss, of course, we lose weight on the drug, the patients lose weight, does it convert ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

There's been growing interest in exploring the broader effects of GLP-1 drugs beyond their use in diabetes and weight loss, too. In December, the FDA approved Zepbound (which has tirzepatide ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type 2 diabetes. Adults without diabetes lost 15% to 20.9% of their body weight, depending on the dosage.

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro ... fact that Eli Lilly's weight loss pipeline is one of ...